|
|
||||||||
J Thorac Cardiovasc Surg 2007;134:29-37
© 2007 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease |
a Institute of Cardiology, Division of Thoracic and Cardiovascular Surgery, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Pierre et Marie Curie-Paris, Paris, France
b Department of Anesthesia and Critical Care, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Pierre et Marie Curie-Paris, Paris, France
c Department of Biostatistics, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Pierre et Marie Curie-Paris, Paris, France.
Received for publication July 27, 2006; revisions received February 7, 2007; accepted for publication February 19, 2007. * Address for reprints: Cosimo DAlessandro, MD, Division of Thoracic and Cardiovascular Surgery, Hôpital La Pitié-Salpêtrière, 47-83 Boulevard de lHôpital, 75 651 Paris Cedex 13, France. (Email: cosimodalessandro{at}wanadoo.fr).
Objective: We sought to evaluate the effect of a strict glycemic control protocol on a series of diabetic patients undergoing surgical myocardial revascularization.
Methods: Between January 2003 and June 2004, 300 diabetic patients undergoing myocardial revascularization received a local protocol of insulin administration (protocol, group P). Patients were divided into 2 risk classes, according to their additive EuroSCORE value: low–moderate risk (0–4) and moderate–high risk (>4). The logistic EuroSCORE algorithm was used to calculate the expected probability of death. A control group was selected, including a series of 300 consecutive diabetic patients (no protocol group, group NP) who underwent coronary artery bypass grafting between March 2001 and September 2002, just before the introduction of the protocol. A propensity analysis was performed to control for selection bias.
Results: Both groups showed similar EuroSCORE risk profiles: mean additive and logistic EuroSCORE values were 4.16 and 4.29 in group P versus 3.93 and 3.91 in group NP. Observed and expected mortalities of group P were 0.6% versus 1.8% (low–moderate risk), 2.5% versus 8.0% (moderate–high risk, P = .03), and 1.3% versus 4.3% (entire group, P = .01). Observed and expected mortalities of group NP were 1.6% versus 1.9% (low–moderate risk), 8.3% versus 7.5% (moderate–high risk), and 4.0% versus 3.9% (entire group). Logistic regression confirmed observed mortality in group P to be significantly lower than the expected logistic EuroSCORE mortality. After risk adjustment, the protocol allowed us to reduce the mortality odds by 72% (odds ratio, 0.282; 95% confidence interval, 0.092–0.859; P < .03). Subgroup analysis for moderate- to high-risk patients showed the protocol to improve mortality (odds ratio, 0.24; P < .05), whereas no significant improvement was found in low- to moderate-risk patients. Addition of the propensity score to the multivariable analysis did not significantly displace P values and odds ratios. Sensitivity analysis of patients who underwent coronary artery bypass grafting without additional procedures showed the protocol to maintain its protective effect (odds ratio, 0.15; P < .05).
Conclusion: Optimal glucose control highly reduces EuroSCORE expected mortality in diabetic patients undergoing myocardial revascularization, especially in moderate- to high-risk patients.
This article has been cited by other articles:
![]() |
S. C. Stamou, M. Nussbaum, J. D. Carew, K. Dunn, E. Skipper, F. Robicsek, and K. W. Lobdell Hypoglycemia with intensive insulin therapy after cardiac surgery: Predisposing factors and association with mortality J. Thorac. Cardiovasc. Surg., July 1, 2011; 142(1): 166 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. de Souza Fantin, M. V. Wainstein, C. A. Polanczyk, P. Ledur, C. M. Lazzari, C. Klein, F. S. Hackenhaar, M. S. Benfato, and B. D. Schaan Inflammatory and Oxidative Stress Markers after Intravenous Insulin in Percutaneous Coronary Intervention with Stent in Type 2 Diabetes Mellitus: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., February 1, 2011; 96(2): 478 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Peterfreund and S. Akhtar How Sweet It Is ... (or Isn't)! Anesth. Analg., April 1, 2010; 110(4): 979 - 981. [Full Text] [PDF] |
||||
![]() |
S. Akhtar, P. G. Barash, and S. E. Inzucchi Scientific Principles and Clinical Implications of Perioperative Glucose Regulation and Control Anesth. Analg., February 1, 2010; 110(2): 478 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Lazar, M. McDonnell, S. R. Chipkin, A. P. Furnary, R. M. Engelman, A. R. Sadhu, C. R. Bridges, C. K. Haan, R. Svedjeholm, H. Taegtmeyer, et al. The Society of Thoracic Surgeons Practice Guideline Series: Blood Glucose Management During Adult Cardiac Surgery Ann. Thorac. Surg., February 1, 2009; 87(2): 663 - 669. [Full Text] [PDF] |
||||
![]() |
P. Lecomte, L. Foubert, F. Nobels, J. Coddens, G. Nollet, F. Casselman, P. V. Crombrugge, G. Vandenbroucke, and G. Cammu Dynamic Tight Glycemic Control During and After Cardiac Surgery Is Effective, Feasible, and Safe Anesth. Analg., July 1, 2008; 107(1): 51 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Barner Operative Treatment of Coronary Atherosclerosis Ann. Thorac. Surg., April 1, 2008; 85(4): 1473 - 1482. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |